In patients with pemphigus vulgaris and pemphigus foliaceus, adjuvant immunoadsorption did not lessen the time to clinical remission, according to a study.

Enrolled patients had newly diagnosed or relapsing moderate-to-severe pemphigus vulgaris (PV) or pemphigus foliaceus (PF) with PDAI scores of ≥15.

The Phase 3 study, which is the first placebo-controlled trial of a BTK inhibitor in pemphigus, enrolled adult patients with moderate-to-severe pemphigus vulgaris or pemphigus foliaceus.

An additional rituximab dose in patients with pemphigus and at least one predictor of relapse may reduce the relapse rate, according to the results of a multicenter French study.